• Phone: +27834072222
  • E-mail: mark@mbac.co.za
MBAC Logo
  • Home
  • About
  • Our Philosophy
  • Services
    • Medical Device Regulation
      • SAHPRA Requirements
    • ISO13485
    • Market Research
    • Business Development
    • Support Services
  • Contact us
  • Internship
  • News
  • Partners

What’s wrong with NHI?

Comment, In the News, NHI
How will Medical Devices be affected by the National

The original article from Business Day looks at various technical, economics, ideological and common sense problems with the Bill.  I however think of the Medical Device Industry and to a lesser extent the supply of pharmaceuticals in the South African Market, and wonder how they will be impacted.

Mention is made in the bill of “central procurement” and appears to lump medical device importers and manufacturers into “suppliers”.  The question then arrises if the Bill actually suggests that the NHI fund will procure medical devices to supply to healthcare providers to then use?  What about their (the hospitals and doctors) having to manage costs as reimbursement will be via DRGs?

Procurement for public sector hospitals, currently a provincial competency, often results in stock shortages and irrational procurement practices which leave capital equipment fallow due to the lack of associated consumable devices being available.

DRS or Diagnosis Related Groups is a reimbursement methodology which calculates the value of reimbursement on a “Global Fee” basis ie for a broken leg a certain amount will be paid, irrespective of the actual costs associated with the treatment of that event. 

Surely medical devices used in the treatment of this broken leg and the costs thereof should be managed by the provider responsible for providing the treatment?

Then we consider the provision for pricing regulations – through a previously mentioned pricing committee or the expansion of Single Exit Prices to Medical Devices.  That too is unclear.  In the previous iteration of the Pricing Committee, healthcare providers (hospitals and doctor groups) will enter into a negotiation with the Department of Health Pricing Committee to set prices – no provision is made for representation of Medical Devices or Pharmaceutical industry in that committee although it is quite reasonable to think that prices of devices and medicines (perhaps not medicines due to Single Exit Pricing) will be included in the cost of service provision and therefore into DRG reimbursement amounts.

There is already a major inequity in the relative power of hospital groups, funders as opposed to the fragmented Medical Device Industry.  The only representative bodies are SAMED and MDMSA – this this is a voluntary association which represents a very small number of suppliers in the South African Market – albeit high in the overall value of imports as most of the large multinationals are members of SAMED.  Competition law also prevents groups of medical device companies either independently or through SAMED from negotiating prices.

The majority of Medical Device companies in South Africa are micro enterprises.

Moreover, Medical Device regulations and amendment to the Medicines and Related Substances Control Act 101 of 1965 makes provisions for international tendering.  This opens the potential for the NHI to procure medical devices on the international market, thereby sidelining the local medical device industry.

Industry representatives that I have spoken to generally speaking are sceptical of what will happen and when.  All are of the opinion that they have been squeezed by hospitals and funders for so long, that this is nothing much new.  There is however also a possitivity around the potential for extending healthcare services into underserviced markets, which will theoretically present an opportunity for the sector.

Time will tell.

Business Day Article

Related

12/09/2019 MDMSA, SAMED, SEP

Previous
Next

Recent Posts

  • Hand Sanitisers
  • COVID-19 exposes our “covert” healthcare crisis
  • Coronavirus Q&A: Will rapid antibody tests save SA?
  • Covid-19: Opportunity for Investment in South Africa’s healthcare sector
  • The unknowns of NHI are exactly what we should be afraid of

Follow me on Twitter

My Tweets

Contact

Telephone:  +27 (0)11 4676673

Fax: 0866842410

Cube Workspace, 9 The Straight Road, Pineslopes, Johannesburg

P. O. Box 145, Magaliessig, 2067

Links

T&C’s

Admin Login

Highlight

ISO 13485 Audit and Implementation

Authorised Representatives for Regulatory Compliance

MBAC provides Medical Device Importer/Distributor Establishment Licensing and Product Registration through Afrihealth

Copyright: MBAC 2019

Theme : Consulting Company WordPress Theme